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Objectives. This study explored the mechanisms linking clinical
and precordial echocardiographic predictors to thromboembolism
in atrial fibrillation (AF) by assessing transesophageal echocar-
diographic (TEE) correlations.
Background. Clinical predictors of thromboembolism in pa-
tients with nonvalvular AF have been identified, but their mech-
anistic links remain unclear. TEE provides imaging of the left
atrium, its appendage and the proximal thoracic aorta, potentially
clarifying stroke mechanisms in patients with AF.
Methods. Cross-sectional analysis of TEE features correlated
with low, moderate and high thromboembolic risk during aspirin
therapy among 786 participants undergoing TEE on entry into the
Stroke Prevention in Atrial Fibrillation III trial.
Results. TEE features independently associated with increased
thromboembolic risk were appendage thrombi (relative risk [RR]
2.5, p 5 0.04), dense spontaneous echo contrast (RR 3.7, p <
0.001), left atrial appendage peak flow velocities <220 cm/s (RR
1.7, p 5 0.008) and complex aortic plaque (RR 2.1, p < 0.001).
Patients with AF with a history of hypertension (conferring
moderate risk) more frequently had atrial appendage thrombi
(RR 2.6, p < 0.001) and reduced flow velocity (RR 1.8, p 5 0.003)
than low risk patients. Among low risk patients, those with
intermittent AF had similar TEE features to those with constant
AF.
Conclusions. TEE findings indicative of atrial stasis or throm-
bosis and of aortic atheroma were independently associated with
high thromboembolic risk in patients with AF. The increased
stroke risk associated with a history of hypertension in AF
appears to be mediated primarily through left atrial stasis and
thrombi. The presence of complex aortic plaque distinguished
patients with AF at high risk from those at moderate risk of
thromboembolism.
(J Am Coll Cardiol 1998;31:1622–6)
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Nonvalvular atrial fibrillation (AF) carries a substantial risk of
arterial thromboembolism, but the absolute rate varies widely
within the spectrum of patients with this arrhythmia. Clinical
and precordial echocardiographic predictors of thromboembo-
lism in AF have previously been identified (1–4), but the
mechanisms linking these predictors with thromboembolic
risks are incompletely defined. For example, hypertension is a
strong, consistent, independent risk factor for stroke in pa-
tients with AF, increasing stroke rates far beyond that associ-
ated with hypertension in patients without AF (1,3,4), but the
pathophysiologic mechanism underlying this multiplicative ef-
fect is obscure.
Transesophageal echocardiography (TEE) offers unique
imaging resolution of the left atrium and its appendage and the
thoracic aorta. Thus, TEE has been extensively used as a tool
to detect potential sources of embolism. In the Stroke Preven-
tion in Atrial Fibrillation (SPAF) III study, patients with AF
with high, moderate and low rates of thromboembolism receiv-
ing aspirin therapy were successfully stratified on the basis of
their clinical and precordial echocardiographic features (4,5).
In the present analysis, we identified TEE correlates of throm-
boembolic risk in a broad range of patients with AF. In
addition, TEE features associates with individual predictors of
increased thromboembolic risk were examined to explore links
with mechanisms.
Methods
Study group. The design and the main results of the SPAF
III study have been described in detail elsewhere (5,6). Pa-
tients with AF receiving aspirin therapy were prospectively
stratified into risk groups using the scheme presented in Figure
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1. High risk patients were characterized by one or more of the
following: 1) women .75 years of age, 2) systolic hypertension
.160 mm Hg measured on two occasions at entry, 3) impaired
left ventricular function (clinical congestive heart failure within
100 days of entry or M-mode echocardiographic fractional
shortening #25%), or 4) previous thromboembolism. Patients
without these risk factors were further divided into those with
a history of hypertension (moderate risk) and those without a
history of hypertension (low risk) on the basis of a priori
planned secondary analysis (6). Longitudinal follow-up of low
and moderate risk patients with AF receiving aspirin, and high
risk participants receiving aspirin plus low doses of warfarin
(which proved ineffective in protecting against stroke) or
adjusted-dose warfarin, confirmed prospectively the validity of
this risk stratification scheme (4,5). Classification and treat-
ment assignment were determined before the TEE examina-
tion and not influenced by its findings.
Participation required signed informed consent according
to federal and local regulations governing research involving
humans.
TEE. Participants in the SPAF III study were encouraged
to undergo TEE within 3 months of study entry, and 41% (n 5
786) agreed to do so (48%, 42% and 37% of high, moderate
and low risk participants, respectively). TEE studies were
performed on average at 26 days after entry according to
specific protocols for acquisition and interpretation (7). Com-
mercially available ultrasound equipment was used, with bi-
plane or multiplane transducers operating at a standard fre-
quency of 5.0 MHz on gray-scale imaging. The TEE features
were recorded according to standardized criteria among all 18
participating centers, and are described in detail elsewhere (7).
Left atrial appendage (LAA) area was obtained by planimetry
from the transverse (zero degree) view. Spontaneous echo
contrast (SEC) was defined as a pattern of slowly swirling
intracavitary echodensities imaged with gain settings adjusted
to distinguish background noise and classified as dense when
continuously present at standard gain. Aortic plaque was
categorized as either simple (sessile) or complex based on
features of mobility, ulceration, pedunculation or thickness
$4 mm and could be located in the ascending, transverse or
proximal descending segment (i.e., not just proximal to the
origins of the cerebral vessels) (7). Analyses reported here are
based on image interpretation at the local clinical laboratories.
All TEE characteristics were concealed from the echocardiog-
raphers during recruitment and data acquisition, avoiding bias
at the time of imaging interpretation.
About half of participants undergoing TEE were receiving
warfarin before study entry (Table 1), and half of high risk
patients were assigned to warfarin after enrollment. In order to
characterize the frequency of LAA thrombus in the absence of
warfarin effect (11), TEE studies carried out within 14 days of
a patient receiving adjusted-dose warfarin (n 5 311), either
randomized or taking at baseline, were excluded from the
analyses of LAA thrombus.
Although diabetes mellitus and intermittent (as opposed to
continuous) AF were not found to be independent predictors
of thromboembolism during aspirin therapy in SPAF I and
SPAF II trials (8), these two factors have been associated with
stroke risk in AF by other investigators (3,9). Thus, we took
this opportunity, using SPAF III data, to reanalyze the role of
diabetes and intermittent AF by correlating them with TEE
features and thromboembolic risks.
Statistical analysis. Patient characteristics were compared
across the three risk groups using a Mantel-Hantsel test for
trend for categorical variables and analysis of variance for
continuous variables. Individual groups were then compared
using a chi-square test (or Fisher exact test if any expected cell
value was ,5) or two-tailed sample t test. TEE characteristics
independently predictive of risk group were determined by
fitting a polychotomous logistic regression model with the
moderate risk group as the reference group (EGRET statisti-
cal software, Cytel Corporation). All variables were placed in
the model and terms that were statistically insignificant (log
likelihood ratio test) were then eliminated (or set equal). A
separate analysis was also done using a forward stepwise
logistic regression model (log likelihood ratio test) to identify
features of moderate and high risk patients (combined group)
relative to low risk (SPSS/PC, SPSS Inc.). Significance was
accepted at the p 5 0.05 level and all tests were two-tailed. No
adjustment was made for multiple comparisons.
Figure 1. Observed thromboembolic rates in patients receiving aspirin
according to risk strata among SPAF III participants undergoing TEE.
Rate in high risk group is for patients receiving combination therapy.
BP 5 blood pressure; CHF 5 congestive heart failure; FS 5 fractional
shortening by precordial echocardiography.
Abbreviations and Acronyms
AF 5 atrial fibrillation
LAA 5 left atrial appendage
RR 5 relative risk
SEC 5 spontaneous echo contrast
SPAF 5 Stroke Prevention in Atrial Fibrillation
TEE 5 transesophageal echocardiography (echocardiographic)
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Results
Patients. Among the 786 participants undergoing TEE at
entry, patient features differed substantially according to risk
stratum (Table 1). As expected, high risk patients more
frequently had the clinical and precordial echocardiographic
features used as criteria for increased thromboembolic risk.
Correlates of thromboembolic risk. As indicated in Table
2, LAA thrombi increased in frequency from 3% to 8% to 15%
(p , 0.001) between participants categorized as low, moderate
and high risk, respectively. Dense SEC and peak LAA flow
velocities were also univariately associated with risk stratum
(p , 0.001), but the cross-sectional area of the LAA was not.
The presence of aortic plaque, particularly plaque classified as
complex, was more frequent in high risk patients with AF than
those at low or moderate risk (Table 2). Figure 2 illustrates the
frequency of TEE findings versus thromboembolic risks. LAA
abnormalities (presence of at least one of thrombus, dense
SEC or reduced flow velocities, p , 0.001), and complex aortic
plaque (p , 0.001) were associated with increased thrombo-
embolic risk (Figure 2).
Independent correlates of thromboembolic risk by multi-
variate analysis. As illustrated in Table 3, LAA thrombus
(relative risk [RR] 2.7, p , 0.001) and reduced LAA peak flow
velocity (RR 1.8, p 5 0.003) were associated with moderate
risk (history of hypertension without high risk features) rela-
tive to low risk status. Complex aortic plaque (RR 2.9, p ,
0.001) and dense SEC (RR 2.7, p , 0.001) were more frequent
in high risk than in moderate risk patients with AF. In patients
with uncontrolled systolic hypertension as their only high risk
feature, complex aortic plaque was significantly more frequent
Table 1. Patient Characteristics of the 786 Transesophageal Echocardiographic Participants
All Patients
(n 5 786)
Low Risk
(n 5 234)
Moderate Risk
(n 5 170)
High Risk
(n 5 382) p Value*
Age (yr)† 69 6 9 67 6 10 66 6 8 71 6 9 , 0.001
Women† 24% 16% 21% 30% , 0.001
History of hypertension† 54% 0% 100% 68% , 0.001
Diabetes 15% 9% 18% 18% 0.002
Previous thromboembolism† 19% 0% 0% 40% , 0.001
History of heart failure† 25% 7% 9% 44% , 0.001
Warfarin use before entry 57% 38% 45% 74% , 0.001
Ischemic heart disease 26% 16% 18% 36% , 0.001
Intermittent atrial fibrillation 19% 28% 19% 14% , 0.001
Systolic BP (mm Hg)† 135 6 20 127 6 15 133 6 14 141 6 23 , 0.001
Diastolic BP (mm Hg) 78 6 10 75 6 10 79 6 10 79 6 10 , 0.001
Precordial echocardiography
LA diameter (cm) 4.8 6 0.8 4.6 6 0.7 4.7 6 0.7 4.9 6 0.8 , 0.001
LA diameter .5.0 cm (%) 34% 26% 31% 39% 0.002
FS (%)† 34 6 9 37 6 6 37 6 7 32 6 11 , 0.001
FS with #25%† 15% 0% 0% 32% , 0.001
*For trend in differences between low versus moderate versus high risk status. †Features used to define the risk strata.
Data presented are mean value 6 SD or percent of patients. BP 5 blood pressure; FS 5 fractional shortening by
precordial echocardiography; LA 5 left atrial.
Table 2. Transesophageal Echocardiographic Correlates of
Thromboembolic Risk
Low Risk
(n 5 234)
Moderate Risk
(n 5 170)
High Risk
(n 5 382)
LAA area .8.4 cm2 26% 21% 25%
Dense SEC 4% 10%* 20%†
LAA thrombus‡ 3% 8%* 15%†
LAA peak flow velocity
#20 cm/s
19% 28%* 37%†
Complex aortic plaque 15% 16% 35%†
Any aortic plaque 48% 54% 63%†
Moderate–severe mitral
regurgitation§
11% 14% 19%†
*p , 0.05 comparing low risk versus moderate risk groups. †p , 0.05
comparing low risk versus high risk groups. ‡Excludes those who underwent
transesophageal echocardiography within 2 weeks of receiving warfarin (either
randomized or taking at baseline). §Severe mitral regurgitation was present in
2% of the cohort. LAA 5 left atrial appendage; SEC 5 spontaneous echo
contrast.
Figure 2. Frequency of TEE findings versus thromboembolic risk.
Patients with left atrial abnormalities had at least one of thrombus,
dense SEC or LAA flow velocities #20 cm/s. Gray bars 5 LAA
abnormalities; solid bars 5 complex plaque.
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than in those with a history of hypertension (35% vs. 16%, p 5
0.002). Independent TEE correlates of low versus moderate or
high risk were LAA thrombus (RR 2.5, p 5 0.04), dense SEC
(RR 3.7, p , 0.001), LAA peak flow velocity #20 cm/s (RR
1.7, p 5 0.008) and complex aortic plaque (RR 2.1, p , 0.001).
Characteristics associated with individual high risk fea-
tures. In high risk patients, TEE features did not differ
significantly among individual criteria conferring high risk
status (Table 4). Figure 3 illustrates the frequency of TEE
findings grouped as LAA abnormalities (presence of at least
one of thrombus, dense SEC or reduced flow velocities) and
complex plaque in patients with a single high risk factor.
Influence of diabetes, intermittence of AF and age among
low risk participants. Low risk patients with and without
diabetes had no significant differences in TEE features: the
presence of LAA thrombi was 0% versus 3%, dense SEC was
0% versus 5% and complex aortic plaque was 17% versus 15%,
between those with and without diabetes, respectively. Simi-
larly, intermittent AF was not significantly associated with TEE
features (Table 5). Among low risk patients with AF, age
(assessed as a continuous variable) was associated with com-
plex aortic plaque (72 vs. 65 years, p , 0.001) and to a lesser
extent with dense SEC (72 vs. 66 years, p 5 0.08). There were
too few patients with LAA thrombus to assess its relation with
age among low risk patients for meaningful comparison.
Discussion
TEE features correlate with thromboembolic risk in non-
valvular AF and provide clues linking risk factors to mecha-
nisms. Patients categorized as moderate risk on the basis of a
history of hypertension had a substantially higher frequency of
LAA thrombi, reduced atrial appendage velocity, and dense
SEC than low risk patients. Hence, the association between
hypertension and increased thromboembolic risk in patients
with AF appears to be mediated, at least in part, by emboli
originating in the LAA (10). The prevalence of complex plaque
in the thoracic aorta differed between patients with AF at high
versus moderate risk. Because most of these plaques were
located distal to the origins of the cerebral vessels, making
them unlikely sources of embolism, this observation suggests
Table 3. Independent Transesophageal Echocardiographic
Correlates of Thromboembolic Risk: Multivariate Analysis*
Risk Group
Relative
Risk†
p
Value
Moderate vs. low risk
LAA thrombus 2.7 , 0.001
LAA peak flow velocity #20 cm/s 1.8 0.003
High vs. moderate risk
Complex aortic plaque 2.9 , 0.001
Dense SEC 2.7 , 0.001
Moderate1high vs. low risk
LAA thrombus 2.5 0.04
Dense SEC 3.7 ,0.001
LAA peak flow velocity ,20 cm/s 1.7 0.008
Complex aortic plaque 2.1 , 0.001
*Independent correlates and their relative risks were similar when those who
underwent transesophageal echocardiography within 2 weeks of receiving war-
farin were excluded. †Relative likelihood of being in the risk group, not of
thromboembolism. LAA 5 left atrial appendage; SEC 5 spontaneous echo
contrast.
Table 4. Transesophageal Echocardiographic Characteristics
Associated With Individual High Risk Features*
Prior Th Emb
(n 5 74)
Women .75
(n 5 33)
Systolic
HTN
(n 5 58)
Poor LV
Function
(n 5 108)
Dense SEC 22% 12% 10% 19%
LAA thrombus† 19% 0% 10% 12%
LAA peak flow velocity
#20 cm/s
40% 37% 33% 35%
Complex aortic plaque 38% 21% 35% 26%
*Patients with more than one high risk feature are excluded. Transesopha-
geal echocardiographic (TEE) characteristics were not significantly different
among individual high risk features. †Excludes those undergoing TEE within 2
weeks of receiving warfarin (either randomized or taking at baseline). HTN 5
hypertension; LAA 5 left atrial appendage; LV 5 left ventricular; SEC 5
spontaneous echo contrast; Th Emb 5 thromboembolism.
Figure 3. Frequency of TEE findings according to criteria classified as
high risk. Participants with more than one high risk feature were
excluded. Patients with left atrial abnormalities had at least one of
thrombus, dense SEC or LAA flow velocities #20 cm/s. Gray bars 5
LAA abnormalities; solid bars 5 complex plaque.
Table 5. Transesophageal Echocardiographic Characteristics of Low
Risk Patients With Intermittent Atrial Fibrillation
Intermittent AF
SR at TEE
(n 5 38)
Intermittent AF
AF at TEE
(n 5 27)
Constant AF
(n 5 169)
Dense SEC 0% 4% 6%
LAA thrombus* 3% 10% 1%
LAA peak flow velocity
#20 cm/s†
6% 17% 22%
Complex aortic plaque 19% 19% 14%
*Excludes those undergoing TEE within 2 weeks of receiving adjusted dose
warfarin. †p , 0.05 for trend. AF 5 atrial fibrillation; LAA 5 left atrial
appendage; SEC 5 spontaneous echo contrast; SR 5 sinus rhythm; TEE 5
transesophageal echocardiography.
1625JACC Vol. 31, No. 7 ZABALGOITIA ET AL.
June 1998:1622–6 TEE AND THROMBOEMBOLIC RISK IN ATRIAL FIBRILLATION
that an extracardiac pathologic mechanism, directly or indi-
rectly, is an important mediator of thromboembolism in high
risk patients with AF (11).
Dense SEC is associated with reduced flow velocity in the
left atrium and with atrial thrombi formation (11) and is a
marker of blood flow stasis in patients with AF. When com-
paring patients at low risk with those at moderate or at high
risk, LAA thrombus, reduced LAA flow velocities and dense
SEC were each independent TEE predictors, further confirm-
ing risk stratification. Thus, patients with AF at moderate or
high risk were distinguished by abnormalities found within the
left atrium (thrombus, dense SEC and reduced appendage
emptying velocity), and by complex aortic plaque. In support of
this observation, follow-up of these high risk patients treated
with low doses of warfarin plus aspirin confirmed the predic-
tive value of dense SEC, LAA thrombi and complex aortic
plaque in the subsequent development of stroke (11).
Previous studies have shown little correlation between left
atrial diameter by precordial echocardiography with thrombo-
embolism in nonvalvular AF (8), and our results additionally
revealed a lack of association between LAA cross-sectional
area and stroke risk in patients with AF. Taken together, these
data suggest that functional attributes of the left atrium are
more important than its size in predicting thromboembolic
risk.
TEE correlates of individual high risk criteria, undertaken
to explore its mechanistic links, were not illuminating. For
example, it remains unclear why elderly women without other
risk factors carry a high risk of thromboembolism. On the
other hand, left ventricular dysfunction is a consistent predic-
tor of thromboembolism in patients with AF (12), and both
atrial and aortic abnormalities were more frequent in these
patients.
Study limitations. In multivariate models, the estimates of
predictive strength of features with a low prevalence (e.g.,
LAA thrombi in low risk patients with AF) may be influenced
by less specific but more prevalent variables (e.g., dense SEC).
Hence, our estimates of the strength of correlations of LAA
thrombi and dense SEC with thromboembolic risk may be
affected by this interaction. Similarly, the low frequency of
severe mitral regurgitation impaired the ability to accurately
characterize its relation to thromboembolic risk. Even so, it
seems clear that abnormalities of the left atrium predisposing
to stasis or thrombus formation, or both, are important differ-
ences between patients with AF at low and those at high risk of
thromboembolism.
Clinical implications. These TEE correlations strongly
support a relation between left atrial stasis, thrombus forma-
tion and stroke risk in patients with nonvalvular AF and
suggest that factors outside of the atrium may contribute to the
thromboembolic risk, particularly in high risk patients with AF.
It is possible that efforts to restore and maintain sinus rhythm
in high risk patients with AF may not completely mitigate the
increased risk of stroke if embolism from extracardiac sources
is the cause.
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